Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/24574
Title: A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma
Authors: Burton, C.
Linch, D.
Mouncey, P.
Smith, P.
Hoskin, P.
Milligan, D.
Dyer, M. J. S.
Hancock, B.
Qian, W.
MacLennan, K.
Jack, A.
Webb, A.
Cunningham, D.
First Published: 28-Feb-2006
Publisher: Cancer Research UK, Nature Publishing Group:
Citation: British Journal of Cancer, 2006, 94 (6), pp. 806-813
Abstract: The management of older patients with aggressive non-Hodgkin's lymphoma presents a challenge to the physician. Age is a poor prognostic indicator, due to reduced ability to tolerate and maintain dose-intensive chemotherapy. Generally, older patients demonstrate a lower response rate, reduced survival and increased toxicity, although the majority of large randomised trials exclude older patients. This randomised trial was conducted in patients 60 years or over to compare CHOP (cyclophosphamide 750 mg m−2, doxorubicin 50 mg m−2, vincristine 1.4 mg m−2, prednisolone 100 mg) with PMitCEBO (mitoxantrone 7 mg m−2, cyclophosphamide 300 mg m−2, etoposide 150 mg m−2, vincristine 1.4 mg m−2, bleomycin 10 mg m−2 and prednisolone 50 mg). Due to the myelosuppressive nature of these regimens, patients were also randomised to the addition of G-CSF. The formal results of this trial with long-term follow-up are now reported. Data were analysed to assess efficacy and toxicity. Overall response rate was 84% in the CHOP arm and 83% in the PMitCEBO arm, with overall response rates of 83% for the use of G-CSF and 84% for no G-CSF. At median 44 months follow-up, there was no significant difference in failure-free, progression-free or overall survival between the CHOP and PMitCEBO arms. At 3 years, the actuarial failure-free survival was 44% in CHOP recipients and 42% in PMitCEBO recipients and the 3-year actuarial overall survival was 46% and 45% respectively. There was no significant difference in the failure-free, progression-free or overall survival with the addition of G-CSF.
DOI Link: 10.1038/sj.bjc.6602975
ISSN: 0007-0920
eISSN: 1532-1827
Links: http://hdl.handle.net/2381/24574
http://www.nature.com/bjc/journal/v94/n6/full/6602975a.html
Type: Journal Article
Rights: Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
Appears in Collections:Published Articles, Dept. of Cancer Studies and Molecular Medicine



Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.